How have leading #pharmaceutical companies managed their finances over the past decade to drive innovation and ROI? Our latest analysis reveals the spending patterns of the top 15 companies in 2023. Discover how they balance investment in R&D with strategic #acquisitions and #licensing deals to achieve the best results. 💰 Download now: https://ow.ly/U8TV50SlJJh
Evaluate Ltd
Information Services
Evaluate provides trusted commercial intelligence and predictive analytics to the pharmaceutical industry
About us
Evaluate provides trusted commercial intelligence and predictive analytics for the pharmaceutical industry. We help our clients to refine and transform their understanding of the past, present and future of the global pharmaceutical market to drive better decisions. Evaluate solutions give you the time and confidence to turn understanding into insight, and insight into action: Evaluate Omnium - provides a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, delivering game-changing insight into pharma asset potential. EvaluatePharma - the trusted global view of the pharmaceutical market’s past, present and future performance with consensus forecasts to 2026, company financials, pipelines, deals and more. @EvaluatePharma EvaluateMedTech - tracks, benchmarks, and forecasts global performance for the medical device and diagnostic industry with consensus forecasts to 2024, company financials and more. Evaluate Custom Solutions - improve your strategic decision-making with customised solutions and deep insights that draw on our industry expertise and trusted commercial intelligence. Explore Evaluate at www.evaluate.com Twitter: @EvaluatePharma
- Website
-
http://www.evaluate.com
External link for Evaluate Ltd
- Industry
- Information Services
- Company size
- 51-200 employees
- Headquarters
- London
- Type
- Privately Held
- Founded
- 1996
- Specialties
- pharma business analysis, pharma licensing deals, pharma consensus forecasts, biotech business analysis, pharma competitive intelligence, medtech consensus forecasts, pharma business developement, pharma, biotech, medtech news, pharma R&D analysis, and pharma data
Locations
-
Primary
3 More London Riverside
London, SE1 2RE, GB
-
60 State St
Boston, Massachusetts 02109, US
-
Akasaka Garden City 4F, 4-15-1 Akasaka,
Tokyo, Tokyo 107-0052, JP
Employees at Evaluate Ltd
Updates
-
If you've not read our brand new World Preview #report yet, there's a handy summary of the findings about the R&D #pharma pipeline by our friends Fierce Biotech. Take a look: https://lnkd.in/e34AvGgb
-
Will you be attending the eagerly awaited World Preview #webinar today? You're not going to want to miss it! 👉 Click here to register: https://ow.ly/suy950SztXr 📺 Click here to log into the auditorium: https://ow.ly/eiGm50SztXp
-
🌟 Exciting news! 🌟 The annual World Preview #report from Evaluate Ltd is now live. Featuring #pharma forecasts to 2030 and buckets of expert analysis on the data, the report provides fantastic insight into the therapy areas driving growth, the top companies and drugs, market landscape and much more. Download your copy now! https://lnkd.in/gMe5hqD7
-
Over the last 10 years, large #pharma companies have spent an average of $120bn across R&D and business development investments. Which companies have been most effective at deploying capital across M&A, licensing and R&D? In this new #blog post, Daniel Chancellor finds out. Read now: https://ow.ly/FU5Z50Sx4i7
Who’s winning in the battle for efficient capital deployment?
evaluate.com
-
Last year's unpredictable times have – for the most part – settled down, bringing steadier trends into play. Download the World Preview 2024 #Infographic to see which drugs, therapy areas, breakthroughs and broader developments are set to shape the pharma market’s future. 👉 https://ow.ly/jn5R50SvNQV
World Preview 2024 – Pharma’s Growth Boost
evaluate.com
-
In the competitive landscape of drug development and commercialisation, making strategic decisions that bring value to your stakeholders and patients is crucial. Evaluate Ltd's tailored commercial solutions help to provide: 📊 Objective risk and return analysis to ensure the long-term health of your pipeline. 🔍 Streamline your search and screening process for in-licensing and out-licensing opportunities, leading to successful deals. 🤝 Partnerships that drive innovation and help you achieve your strategic goals more efficiently. Find our how our experts can help you and your strategy today: https://lnkd.in/eW8xEA55 #Pharmaceuticals #Innovation #Strategy
-
Our upcoming World Preview #report forecasts the prescription drug market will hit over $1.7 trillion in worldwide sales in 2030 – that’s a growth rate of 7.7%. What’s driving it? It’s not ALL obesity, there are several therapy areas in the spotlight and we’ll digging into the detail in the report when it’s released next week! Stay tuned! 📢 Pre-register for the report and you'll receive it as soon as it launches: https://lnkd.in/emS2DMJk #Biopharma #Biotech
-
Beyond the patent cliff: Are your models forecasting the full market picture? Will your #pharmaceutical #forecasts withstand the impact of a patent expiry, whether it's your product or a competitor's? J+D Forecasting's new #report explores how to incorporate these market shifts into your forecasting models. Learn more: https://ow.ly/7LNC50SrMrk
Evaluate | Loss of Exclusivity Report
discover.evaluate.com
-
Our World Preview #webinar is just a couple of weeks away and our expert panel have been planning! For a sneak peek of what you can expect of the session, check out this new #blog by panellist Paul Verdin who shares a few of #pharma themes under discussion. Click here to read now: https://lnkd.in/gCJxbXZF